COVID-19：AGC Bio､ｍRNA生産を増強：at its Heidelberg（動画）：
COVID-19: AGC Biologics boosts RNA production: at its Heidelberg：
COVID-19：AGC Biologics 提高 RNA 生产：在其海德堡
AGC Biologics社：（本社：米国）
AGC Biologics社は、ＡＧＣバイオ医薬品CDMO*事業子会社です。
mRNA製造サービス提供：
旺盛な需要に対応します。
- 独ハイデルベルグ工場において、
- メッセンジャーRNA(mRNA)の、
- 製造受託サービス提供体制を構築します。
プラスミドDNA(pDNA)の生産：
その原料となるプラスミドDNA(pDNA)生産ラインの増設を決定しました。
2023年中頃の稼働開始を予定しています。
ニュース ｜ AGC
https://www.agc.com/news/detail/1202417_2148.html
AGC Biologics to Build New Messenger RNA Capacity at its Heidelberg Facility
―With Additional Production Capacity for Plasmid-DNA, a Starting Material for Messenger RNA Production―
AGC (AGC Inc.; Headquarters: Tokyo; President: Yoshinori Hirai), a world-leading manufacturer of glass, chemicals, and high-tech materials, has announced that
its biopharmaceutical CDMO* subsidiary, AGC Biologics (United States), is expanding its Heidelberg facility to create capacity for messenger RNA (mRNA) projects,
and additional production capacity for plasmid-DNA (pDNA), which one of its uses is as material for mRNA production.
This expansion
will enable AGC Biologics to better service the needs of the growing pDNA and mRNA global markets.
The facility’s new capabilities
will be fully operational in around mid-2023.
In addition to this expansion,
AGC Biologics
is expanding its cell and gene therapy capacity at the Milan site
and has acquired a cell and gene therapy manufacturing facility in Longmont, Colorado, U.S., as previously announced.
Through these investments,
AGC Biologics
is accelerating its growth as one of the few CDMOs in the world that can provide integrated end-to-end services for the manufacture of cell and gene therapies.
News ｜ AGC
https://www.agc.com/en/news/detail/1202418_2814.html
AGC Biologics Enters Agreement to Acquire Facility in Longmont, Colorado, U.S. ｜ News ｜ AGC